June 29, 2022

Medical Trend

Medical News and Medical Resources

Pfizer COVID-19 vaccines benefit from Chinese scientists’ sequencing

Pfizer COVID-19 vaccines benefit from Chinese scientists’ sequencing of the virus’s whole genome  

Pfizer COVID-19 vaccines benefit from Chinese scientists’ sequencing of the virus’s whole genome. The British “Guardian” confirmed: Pfizer and other vaccines benefited from Chinese scientists’ sequencing of the whole genome of the virus.

U.S. Pfizer COVID-19 vaccines benefit from Chinese scientists' sequencing of the virus's whole genome

The COVID-19 pneumonia epidemic is still spreading around the world. The fight against the epidemic requires a global response and the cooperation of scientific researchers from all countries. The British “Guardian” published an article on December 6 that traced the latest progress of global scientists from the discovery of virus structure to vaccine research, and believed that the researcher of the Institute of Infectious Diseases of the Chinese Center for Disease Control and Prevention, and the adjunct professor of Shanghai (Fudan University) Public Health Clinical Center Zhang Yongzhen and his team’s early research on virus structure has made important contributions to the global fight against viruses.

The research results of Chinese scientists provide the scientific community with “opportunities to fight back against the virus”

According to the report, on January 3, Zhang Yongzhen’s team received a box containing a swab from a patient who suffered from a rare and sometimes fatal respiratory disease. The medical department wants to understand the reasons for the sharp increase in the number of cases and how the disease spreads.

In the next 48 hours, Zhang Yongzhen’s team worked almost uninterruptedly, using advanced sequencers to crack the RNA gene fragments of the virus, and believed that it was this RNA that caused the virus outbreak. Decoding the 28,000 letters of this RNA can analyze the nature and behavior of this new pathogen.

On January 5, Zhang Yongzhen’s team detected a new type of coronavirus from the specimens and obtained the entire genome sequence of the virus through high-throughput sequencing. In the next few days, Zhang Yongzhen’s team published the research results on the Virological Organization website (virological.org), becoming the first team in the world to publish the sequence of the virus.

By sequencing the genome of the virus, Zhang Yongzhen’s team has provided scientists with vital information to isolate and replicate various fragments of the virus and use these fragments to develop vaccines. The Guardian quoted Adam Finn, a professor at the University of Bristol, as saying that Zhang Yongzhen’s research was “critical to what happened next. Without the information he provided, no one could start developing a vaccine”.

The Guardian also commented that the discovery of Zhang Yongzhen’s team not only simply pointed out that the virus will cause chaos and death, but the early cracking of the virus structure by his team provided an opportunity for the scientific community to fight back against the virus and provide a vaccine. Research provides the possibility.

The whole genome sequence of the virus provides the possibility for vaccine development

According to the Guardian, the spike protein, which plays a key role in the replication of (new coronavirus) Sars-CoV-2, has quickly become the focus of most vaccine manufacturers. Researchers infer that if they can help the human body produce a strong immune response and prevent the spike protein from entering human cells, the development of the virus will stop. But to do this, it is necessary to find a way to implant spike protein fragments into the body to stimulate the body to produce antibodies against it. Most COVID-19 vaccine projects have adopted this strategy, albeit in different ways.

The German biotech company, which develops RNA vaccines to fight cancer, realizes that it can apply its expertise to the fight against the COVID-19 epidemic. Using the gene sequence provided by Zhang Yongzhen’s team, a German biotech company supported by Pfizer Pharmaceuticals Co., Ltd. packaged the RNA coding fragment of the viral spike protein and injected it into the human body. After these RNA droplets are absorbed by human cells, they instruct the human cell replication mechanism to produce spike protein particles. When this process is discovered by the human immune system, it triggers the production of antibodies.

“The Guardian” said that Moderna in the United States also used a similar method when producing vaccines.

Professor Peter Obenshaw of Imperial College London said: “This is a novel technology, but it is also a very simple technology. Researchers only need to make a chemical chain of RNA and then implant it into the human body. This This is a key reason why the German biotech company and Moderna have achieved results so quickly.


Disclaimer of medicaltrend.org